Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology
Prostate cancer, the most frequent cancer in man, is an adenocarcinoma sensible to chemical castration in more than 80% of cases due to its hormonal dependency. Androgen deprivation is the treatment for advanced cancer and can be associated with radiotherapy locally or in locally advanced situations...
Saved in:
Published in | Cancer radiothérapie Vol. 20; no. 5; pp. 405 - 410 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | French |
Published |
France
01.07.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Prostate cancer, the most frequent cancer in man, is an adenocarcinoma sensible to chemical castration in more than 80% of cases due to its hormonal dependency. Androgen deprivation is the treatment for advanced cancer and can be associated with radiotherapy locally or in locally advanced situations. Multidisciplinary therapeutic choice depends on patient age and co-morbidities and clinical stage. The impact of hormonal treatment confers varied side effects and cardiovascular effects are now better known. Responsible mechanisms of this cardiotoxicity are at the same time direct but also indirect by metabolic thermogenic effects. Analysis of these clinical or biological effects, their correlations to the used type of hormonal treatment and the possible precautions of prescription will be detailed in this analysis of the literature. The collaboration of the oncologist or the urologist with the cardiologist becomes necessary and the existence of a unit of oncocardiology could improve the evaluation of the risk-benefit balance and the tolerance of the treatment. |
---|---|
AbstractList | Prostate cancer, the most frequent cancer in man, is an adenocarcinoma sensible to chemical castration in more than 80% of cases due to its hormonal dependency. Androgen deprivation is the treatment for advanced cancer and can be associated with radiotherapy locally or in locally advanced situations. Multidisciplinary therapeutic choice depends on patient age and co-morbidities and clinical stage. The impact of hormonal treatment confers varied side effects and cardiovascular effects are now better known. Responsible mechanisms of this cardiotoxicity are at the same time direct but also indirect by metabolic thermogenic effects. Analysis of these clinical or biological effects, their correlations to the used type of hormonal treatment and the possible precautions of prescription will be detailed in this analysis of the literature. The collaboration of the oncologist or the urologist with the cardiologist becomes necessary and the existence of a unit of oncocardiology could improve the evaluation of the risk-benefit balance and the tolerance of the treatment. |
Author | Latorzeff, I Jonca, F Rollin, G Guillotreau, J Labarthe, P Pathak, A Ploussard, G Beauval, J-B |
Author_xml | – sequence: 1 givenname: I surname: Latorzeff fullname: Latorzeff, I email: i.latorzeff@clinique-pasteur.com organization: Groupe Oncorad-Garonne, service d'oncologie-radiothérapie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France; Groupe Oncorad-Garonne, unité d'oncocardiologie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France. Electronic address: i.latorzeff@clinique-pasteur.com – sequence: 2 givenname: G surname: Ploussard fullname: Ploussard, G organization: Service d'urologie, clinique Saint-Jean-du-Languedoc, 20, route de Revel, 31400 Toulouse, France – sequence: 3 givenname: J surname: Guillotreau fullname: Guillotreau, J organization: Service d'urologie, clinique Pasteur, 45, avenue de Lombez, 31300 Toulouse, France – sequence: 4 givenname: F surname: Jonca fullname: Jonca, F organization: Service d'urologie, clinique Ambroise-Paré, 387, route de Saint-Simon, 31100 Toulouse, France – sequence: 5 givenname: P surname: Labarthe fullname: Labarthe, P organization: Service d'urologie, clinique des Cèdres, château d'Alliez, 31700 Cornebarrieu, France – sequence: 6 givenname: G surname: Rollin fullname: Rollin, G organization: Service d'urologie, clinique d'Occitanie, 20, avenue Bernard-IV, 31600 Muret, France – sequence: 7 givenname: J-B surname: Beauval fullname: Beauval, J-B organization: Service d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France – sequence: 8 givenname: A surname: Pathak fullname: Pathak, A organization: Groupe Oncorad-Garonne, unité d'oncocardiologie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France; Service de cardiologie, clinique Pasteur, 45, avenue de Lombez, 31300 Toulouse, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27344534$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kM1OwzAQhC0EorTwBgj5yCVhHTtOyg1V_EmVuMA52jgbmpLEwXZAfXtCKafRzow-aWfOjnvbE2OXAmIBQt9sY4O9wypOpiuGJAaRHrEzkellpHWaz9jc-y0AaL1MT9ksyaRSqVRnbLtCVzX2C70ZW3TcNf7D8-8mbPjgrA8YiE9sQ45vrOtsjy0PjjB01Idb7jA0vx7x2jqOvKIB3T7jtua2N9bs-a19352zkxpbTxcHXbC3h_vX1VO0fnl8Xt2to0EoESKtSJWVqVKZgKkVlAlkSqQmgRzz0mgQiSyNVAIkIWVJKWqjwCwpK9MaMpILdv3HnR74HMmHomu8obbFnuzoC5FDLvNpCTlVrw7VseyoKgbXdOh2xf8-8gdbwmuI |
ContentType | Journal Article |
Copyright | Copyright © 2016 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved. |
Copyright_xml | – notice: Copyright © 2016 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.canrad.2016.02.015 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Risques cardiovasculaires avec les hormonothérapies pour cancer de la prostate : rationnel pour une unité oncocardiologique |
EISSN | 1769-6658 |
EndPage | 410 |
ExternalDocumentID | 27344534 |
Genre | Journal Article Review |
GroupedDBID | --K --M .~1 0R~ 1B1 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXUO ABBQC ABFNM ABGSF ABMAC ABMZM ABUDA ABXDB ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AENEX AFJKZ AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CGR CUY CVF DU5 EBS ECM EFJIC EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM LN9 M41 MO0 N9A NPM O-L O9- OAUVE OZT P-8 P-9 PC. Q38 R2- RIG ROL RPZ SDF SDG SEM SES SEW SSH SSU SSZ T5K UDS UHS ~G- 7X8 |
ID | FETCH-LOGICAL-p141t-64e4bdcd5320cf40b207415c208a8bc60123bc34103eae72b1fc40c9e7b5f07e3 |
IngestDate | Fri Aug 16 09:46:56 EDT 2024 Sat Sep 28 08:21:18 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Risque cardiovasculaire Cancer de la prostate Cardiovascular risk Hormonothérapie Hormonal treatment Prostate cancer Unit of oncocardiology Unité oncocardiologie |
Language | French |
License | Copyright © 2016 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p141t-64e4bdcd5320cf40b207415c208a8bc60123bc34103eae72b1fc40c9e7b5f07e3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
PMID | 27344534 |
PQID | 1808386693 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1808386693 pubmed_primary_27344534 |
PublicationCentury | 2000 |
PublicationDate | 2016-Jul 20160701 |
PublicationDateYYYYMMDD | 2016-07-01 |
PublicationDate_xml | – month: 07 year: 2016 text: 2016-Jul |
PublicationDecade | 2010 |
PublicationPlace | France |
PublicationPlace_xml | – name: France |
PublicationTitle | Cancer radiothérapie |
PublicationTitleAlternate | Cancer Radiother |
PublicationYear | 2016 |
SSID | ssj0006695 |
Score | 2.0985587 |
SecondaryResourceType | review_article |
Snippet | Prostate cancer, the most frequent cancer in man, is an adenocarcinoma sensible to chemical castration in more than 80% of cases due to its hormonal... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 405 |
SubjectTerms | Androgen Antagonists - adverse effects Cardiologists Cardiology Cardiotoxicity - etiology Humans Male Medical Oncology Oncologists Patient Care Team Prostatic Neoplasms - therapy Risk Assessment |
Title | Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27344534 https://search.proquest.com/docview/1808386693 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZbC2MvY7_b_UKDvQ0P2ZZke2-ltCtt2o2RsLwZSZZpS7CD67z0r9-dZcsx3aDbiwlOIjm6L6dPp-9OhHxKgNKzwoog5oIHPNYcA006KNIy4Sy2GVMY7zi_kCcLfroUy1Fu22WXtPqLuf1jXsn_WBXugV0xS_YfLOsbhRvwGuwLV7AwXO9l48OpmBRl4n222hqTOYBGoqjL2ObzJVDTqbAcQwFNHwl0hb8VymKhl0EeUFfgLLsefOR9LGmAjTYK3msv3V57o9ZXHiQzXMrfWlfx0cdlf6zqzc2NcmJ6f6bXt83ValXjc20m21Sn0L8atcd9ZCKUXsUKE4vzponMAildbfbB3UZsC1Ziy3dyJramYe7Urnc8vAs2XMPqvYJfido82RVdDcU4ow27-Bff8-PFbJbPj5bzh2Q3SjIB6_Pdg7Ofv878dC1lJoacyk74d7flv68-OhYyf0qe9MsHeuCw8Iw8KJvn5NF5L5B4Qa6nkKAdJChCgg6QoA4SdIAE9ZD4Sj0gKACCKjoCgtYlnQLiJVkcH80PT4L-OI1gHfKwDSS3XBemwKNATMmZjjo6aSKWqlQbiexaG2A18BdVNol0WBrOTGYTLUqW2PgV2anqyu4RCh8sIlWEcRQrZDfachViaEBEoixUuE8-DgOWg7vCPShVWcBYHqbA-VMY83ifvHYjma9dXZUcKy1xEfM39_j2W_J4hNw7stM2G_se6GGrP_QG_g1hNWzH |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiovascular+risks+with+prostate+cancer+hormonal+treatment%3A+rationale+for+a+department+of+oncocardiology&rft.jtitle=Cancer+radioth%C3%A9rapie&rft.au=Latorzeff%2C+I&rft.au=Ploussard%2C+G&rft.au=Guillotreau%2C+J&rft.au=Jonca%2C+F&rft.date=2016-07-01&rft.eissn=1769-6658&rft.volume=20&rft.issue=5&rft.spage=405&rft.epage=410&rft_id=info:doi/10.1016%2Fj.canrad.2016.02.015&rft.externalDBID=NO_FULL_TEXT |